A new one-year study in the United States has found that the pirfenidone could help prevent people with type 2 diabetes from suffering damage to their kidneys . The research involved monitoring 77 patients that had been diagnosed with diabetic nephropathy, a principle reason for end-stage kidney disease, and also a common complication of diabetes.
Scientists at the University of California, San Diego School of Medicine, the National Institutes of Health (NIH) and the Mayo Clinic revealed that pirfenidone, an anti-inflammatory and anti-fibrotic medication, could be a viable treatment for people with diabetic nephropathy.
The study published in the Journal of the American Society of Nephrology, examined three groups, one that took a high dose of pirfenidone, one that took a low dose, and a control group, with the rate of decline in kidney function being reviewed for all three. It was found that there was a significant improvement in the group that received a low dose.
Researcher Jeffrey B. Kopp commented "We have previously found that pirfenidone slows progressive loss of kidney function in another chronic kidney disease, called focal segmental glomerulosclerosis."
He added "By extending these findings to the most common chronic kidney disease – diabetic kidney disease – the present study suggests that pirfenidone may have broad utility to help patients maintain kidney function longer."
Pirfenidone shows well in tests for treating kidney disease in diabetics
Wed, 27 Apr 2011
Recommended links
What is covered by Diabetic Health InsuranceHow Diabetes Private Medical Insurance Policies Work
Diabetic Health Insurance - Single Parent Family
Diabetic Health Insurance - Couple
Diabetic Health Insurance - Family
Diabetic Health Insurance - Single Parent Family
Cardiovascular Disease and Prevention
Diabetic Nephropathy
RNIB Scotland warns about diabetic sight loss
ContentMain
